Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag A new study shows baricitinib slows type 1 diabetes progression in young patients, but effects reverse after stopping the drug.

flag A new study finds that baricitinib, a pill used for rheumatoid arthritis and alopecia, may slow type 1 diabetes progression in newly diagnosed patients aged 10 to 30. flag After 48 weeks of daily treatment, participants showed preserved insulin-producing beta cell function, reduced blood sugar swings, and lower insulin needs. flag However, benefits disappeared after stopping the drug, with blood sugar control and insulin use returning to placebo levels by week 96. flag The drug, which calms overactive immune responses, was well-tolerated and taken orally. flag Researchers say results are promising for future trials to see if long-term or early use could delay or prevent type 1 diabetes, with potential approval within five years if larger studies confirm effectiveness. flag Findings are preliminary and not yet peer-reviewed.

3 Articles